News >

Cabozantinib Active as Salvage Therapy in Thyroid Cancer

Jason Harris
Published: Tuesday, Sep 05, 2017

Thyroid cancer Cabozantinib (Cabometyx) demonstrated durable activity in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who progressed on VEGFR-targeted therapy, according to phase II data published in the Journal of Clinical Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x